An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

Trial Profile

An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Acalabrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 12 Dec 2017 Results of exposure response analysis using patient data from this and 6 other studies presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results (as of 28 Feb 2017) assessing the efficacy and safety of Acalabrutinib monotherapy, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results (n=610) of pooled safety analysis of ACE-LY004, ACE-CL001, ACE-WM001, 15H0016, ACE-LY002 ACE-LY-003, ACE-MY001 trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top